Oligomerization requirements for MX2-mediated suppression of HIV-1 infection

Journal of Virology

Volumn 90, Issue 1, 2016, Pages 22-32

  Dicks, Matthew D J ^a   Goujon, Caroline ^b   Pollpeter, Darja ^a   Betancor, Gilberto ^a   Apolonia, Luis ^a   Bergeron, Julien R C ^c   Malim, Michael H ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b University of Montpellier I and II   (France)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MONOMER; MUTANT PROTEIN; MYXOVIRUS RESISTANCE PROTEIN; MYXOVIRUS RESISTANCE PROTEIN 1; MYXOVIRUS RESISTANCE PROTEIN 2; UNCLASSIFIED DRUG; MX2 PROTEIN, HUMAN;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; COVALENT BOND; HINGE REGION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOPRECIPITATION; NONHUMAN; OLIGOMERIZATION; POINT MUTATION; PRIORITY JOURNAL; PROTEIN CROSS LINKING; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION; CELL LINE; DNA MUTATIONAL ANALYSIS; GENETICS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; MOLECULAR MODEL; PHYSIOLOGY; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; VIRUS REPLICATION;

AMINO ACID SUBSTITUTION; CELL LINE; DNA MUTATIONAL ANALYSIS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; MODELS, MOLECULAR; MUTANT PROTEINS; MYXOVIRUS RESISTANCE PROTEINS; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; VIRUS REPLICATION;

EID: 84953924195     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02247-15     Document Type: Article

References (34)

1. Doyle T, Goujon C, Malim MH. 2015. HIV-1 and interferons: who's interfering with whom? Nat Rev Microbiol 13:403-413. http://dx.doi.org/10.1038/nrmicro3449.
2. Schoggins JW, Rice CM. 2011. Interferon-stimulated genes and their antiviral effector functions. Curr Opin Virol 1:519-525. http://dx.doi.org/10.1016/j.coviro.2011.10.008.
3. Goujon C, Moncorgé O, Bauby H, Doyle T, Ward CC, Schaller T, Hué S, Barclay WS, Schulz R, Malim MH. 2013. Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection. Nature 502:559-562. http://dx.doi.org/10.1038/nature12542.
4. Kane M, Yadav SS, Bitzegeio J, Kutluay SB, Zang T, Wilson SJ, Schoggins JW, Rice CM, Yamashita M, Hatziioannou T, Bieniasz PD. 2013. MX2 is an interferon-induced inhibitor of HIV-1 infection. Nature 502: 563-566. http://dx.doi.org/10.1038/nature12653.
5. Liu Z, Pan Q, Ding S, Qian J, Xu F, Zhou J, Cen S, Guo F, Liang C. 2013. The interferon-inducible MxB protein inhibits HIV-1 infection. Cell Host Microbe 14:398-410. http://dx.doi.org/10.1016/j.chom.2013.08.015.
6. Fribourgh JL, Nguyen HC, Matreyek KA, Alvarez FJ, Summers BJ, Dewdney TG, Aiken C, Zhang P, Engelman A, Xiong Y. 2014. Structural insight into HIV-1 restriction by MxB. Cell Host Microbe 16:627-638. http://dx.doi.org/10.1016/j.chom.2014.09.021.
7. Fricke T, White TE, Schulte B, de Souza Aranha Vieira DA, Dharan A, Campbell EM, Brandariz-Nuñez A, Diaz-Griffero F. 2014. MxB binds to the HIV-1 core and prevents the uncoating process of HIV-1. Retrovirology 11:68. http://dx.doi.org/10.1186/s12977-014-0068-x.
8. Liu Z, Pan Q, Liang Z, Qiao W, Cen S, Liang C. 2015. The highly polymorphic cyclophilin A-binding loop in HIV-1 capsid modulates viral resistance to MxB. Retrovirology 12:1. http://dx.doi.org/10.1186/s12977-014-0129-1.
9. Haller O, Kochs G. 2011. Human MxA protein: an interferon-induced dynamin-like GTPase with broad antiviral activity. J Interferon Cytokine Res 31:79-87. http://dx.doi.org/10.1089/jir.2010.0076.
10. Gao S, von der Malsburg A, Paeschke S, Behlke J, Haller O, Kochs G, Daumke O. 2010. Structural basis of oligomerization in the stalk region of dynamin-like MxA. Nature 465:502-506. http://dx.doi.org/10.1038/nature08972.
11. Pitossi F, Blank A, Schröder A, Schwarz A, Hüssi P, Schwemmle M, Pavlovic J, Staeheli P. 1993. A functional GTP-binding motif is necessary for antiviral activity of Mx proteins. J Virol 67:6726-6732.
12. Ponten A, Sick C, Weeber M, Haller O, Kochs G. 1997. Dominantnegative mutants of human MxA protein: domains in the carboxyterminal moiety are important for oligomerization and antiviral activity. J Virol 71:2591-2599.
13. Kochs G, Haener M, Aebi U, Haller O. 2002. Self-assembly of human MxA GTPase into highly ordered dynamin-like oligomers. J Biol Chem 277:14172-14176. http://dx.doi.org/10.1074/jbc. M200244200.
14. Kochs G, Janzen C, Hohenberg H, Haller O. 2002. Antivirally active MxA protein sequesters La Crosse virus nucleocapsid protein into perinuclear complexes. Proc Natl Acad SciUSA99:3153-3158. http://dx.doi.org/10.1073/pnas.052430399.
15. Turan K, Mibayashi M, Sugiyama K, Saito S, Numajiri A, Nagata K. 2004. Nuclear MxA proteins form a complex with influenza virus NP and inhibit the transcription of the engineered influenza virus genome. Nucleic Acids Res 32:643-652. http://dx.doi.org/10.1093/nar/gkh192.
16. Gao S, von der Malsburg A, Dick A, Faelber K, Schröder GF, Haller O, Kochs G, Daumke O. 2011. Structure of myxovirus resistance protein a reveals intra-and intermolecular domain interactions required for the antiviral function. Immunity 35:514-525. http://dx.doi.org/10.1016/j.immuni.2011.07.012.
17. Haller O, Gao S, von der Malsburg A, Daumke O, Kochs G. 2010. Dynamin-like MxA GTPase: structural insights into oligomerization and implications for antiviral activity. J Biol Chem 285:28419-28424. http://dx.doi.org/10.1074/jbc. R110.145839.
18. Dick A, Graf L, Olal D, von der Malsburg A, Gao S, Kochs G, Daumke O. 2015. Role of nucleotide binding and GTPase domain dimerization in dynamin-like myxovirus resistance protein A for GTPase activation and antiviral activity. J Biol Chem 290:12779-12792. http://dx.doi.org/10.1074/jbc. M115.650325.
19. Rennie ML, McKelvie SA, Bulloch EM, Kingston RL. 2014. Transient dimerization of human MxA promotes GTP hydrolysis, resulting in a mechanical power stroke. Structure 22:1433-1445. http://dx.doi.org/10.1016/j.str.2014.08.015.
20. Goujon C, Greenbury RA, Papaioannou S, Doyle T, Malim MH. 2015. A triple-arginine motif in the amino-terminal domain and oligomerization are required for HIV-1 inhibition by human MX2. J Virol 89:4676-4680. http://dx.doi.org/10.1128/JVI.00169-15.
21. Haller O, Staeheli P, Schwemmle M, Kochs G. 2015. Mx GTPases: dynamin-like antiviral machines of innate immunity. Trends Microbiol 23:154-163. http://dx.doi.org/10.1016/j.tim.2014.12.003.
22. Busnadiego I, Kane M, Rihn SJ, Preugschas HF, Hughes J, Blanco-Melo D, Strouvelle VP, Zang TM, Willett BJ, Boutell C, Bieniasz PD, Wilson SJ. 2014. Host and viral determinants of Mx2 antiretroviral activity. J Virol 88:7738-7752. http://dx.doi.org/10.1128/JVI.00214-14.
23. Goujon C, Moncorgé O, Bauby H, Doyle T, Barclay WS, Malim MH. 2014. Transfer of the amino-terminal nuclear envelope targeting domain of human MX2 converts MX1 into an HIV-1 resistance factor. J Virol 88:9017-9026. http://dx.doi.org/10.1128/JVI.01269-14.
24. Melén K, Keskinen P, Ronni T, Sareneva T, Lounatmaa K, Julkunen I. 1996. Human MxB protein, an interferon-alpha-inducible GTPase, contains a nuclear targeting signal and is localized in the heterochromatin region beneath the nuclear envelope. J Biol Chem 271:23478-23486. http://dx.doi.org/10.1074/jbc.271.38.23478.
25. Matreyek KA, Wang W, Serrao E, Singh PK, Levin HL, Engelman A. 2014. Host and viral determinants for MxB restriction of HIV-1 infection. Retrovirology 11:90. http://dx.doi.org/10.1186/s12977-014-0090-z.
26. Schulte B, Buffone C, Opp S, Di Nunzio F, Augusto De Souza Aranha Vieira D, Brandariz-Nuñez A, Diaz-Griffero F. 2015. Restriction of HIV-1 requires the N-terminal region of MxB/Mx2 as a capsid-binding motif but not as a nuclear localization signal. J Virol 89:8599-8610. http://dx.doi.org/10.1128/JVI.00753-15.
27. Melén K, Julkunen I. 1997. Nuclear cotransport mechanism of cytoplasmic humanMxBprotein. J Biol Chem 272:32353-32359. http://dx.doi.org/10.1074/jbc.272.51.32353.
28. Faelber K, Posor Y, Gao S, Held M, Roske Y, Schulze D, Haucke V, Noé F, Daumke O. 2011. Crystal structure of nucleotide-free dynamin. Nature 477:556-560. http://dx.doi.org/10.1038/nature10369.
29. Mitchell PS, Patzina C, Emerman M, Haller O, Malik HS, Kochs G. 2012. Evolution-guided identification of antiviral specificity determinants in the broadly acting interferon-induced innate immunity factor MxA. Cell Host Microbe 12:598-604. http://dx.doi.org/10.1016/j.chom.2012.09.005.
30. Patzina C, Haller O, Kochs G. 2014. Structural requirements for the antiviral activity of the human MxA protein against Thogoto and influenza A virus. J Biol Chem 289:6020-6027. http://dx.doi.org/10.1074/jbc. M113.543892.
31. Buffone C, Schulte B, Opp S, Diaz-Griffero F. 2015. Contribution of MxB oligomerization to HIV-1 capsid binding and restriction. J Virol 89:3285-3294. http://dx.doi.org/10.1128/JVI.03730-14.
32. Merkley ED, Rysavy S, Kahraman A, Hafen RP, Daggett V, Adkins JN. 2014. Distance restraints from crosslinking mass spectrometry: mining a molecular dynamics simulation database to evaluate lysinelysine distances. Protein Sci 23:747-759. http://dx.doi.org/10.1002/pro.2458.
33. Goldstone DC, Walker PA, Calder LJ, Coombs PJ, Kirkpatrick J, Ball NJ, Hilditch L, Yap MW, Rosenthal PB, Stoye JP, Taylor IA. 2014. Structural studies of postentry restriction factors reveal antiparallel dimers that enable avid binding to the HIV-1 capsid lattice. Proc Natl Acad Sci U S A 111:9609-9614. http://dx.doi.org/10.1073/pnas.1402448111.
34. Yap MW, Mortuza GB, Taylor IA, Stoye JP. 2007. The design of artificial retroviral restriction factors. Virology 365:302-314. http://dx.doi.org/10.1016/j.virol.2007.04.005.